Tisotumab vedotin for vulvar cancer that has spread or come back
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called tisotumab vedotin in people with a type of vulvar cancer (squamous cell) that has spread or returned. The drug may help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have vulvar cancer that is squamous cell type and has spread or come back, and you've had up to 2 prior treatments.
- Your cancer cannot be cured with surgery or radiation.
- You have at least one tumor that can be measured on scans, and it's at least 1 cm (or a lymph node at least 1.5 cm).
- Your kidneys, liver, and blood counts must be within certain limits.
- You must be willing to use effective birth control during the study and for 6 months after the last dose.
- You can't have certain eye problems, bleeding risks, or heart conditions listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
Hear when a new Vulvar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.